KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $169.0 million.

  • Alnylam Pharmaceuticals' Net Cash Flow rose 225.15% to $377.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.9 million, marking a year-over-year increase of 575.03%. This contributed to the annual value of $169.0 million for FY2024, which is 381.38% up from last year.
  • Alnylam Pharmaceuticals' Net Cash Flow amounted to $169.0 million in FY2024, which was up 381.38% from -$60.1 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Net Cash Flow ranged from a high of $332.1 million in FY2021 and a low of -$60.1 million during FY2023.
  • For the 3-year period, Alnylam Pharmaceuticals' Net Cash Flow averaged around $54.3 million, with its median value being $53.8 million (2022).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Net Cash Flow surged by 698.42% in 2021 and then crashed by 211.57% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Net Cash Flow (Yearly) stood at -$55.5 million in 2020, then spiked by 698.42% to $332.1 million in 2021, then slumped by 83.79% to $53.8 million in 2022, then plummeted by 211.57% to -$60.1 million in 2023, then spiked by 381.38% to $169.0 million in 2024.